Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to faricimab in diabetic macular edema with suboptimal response to aflibercept
TCTR20240322005Phase 3Recruiting
- Sponsor
- Faculty of Medicine Siriraj Hospital, Mahidol University
- Start
- Nov 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of faricimab in diabetic macular edema (DME), sponsored by Faculty of Medicine Siriraj Hospital, Mahidol University. Started Nov 2023; status: recruiting.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on TCTR20240322005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240322005.